NCT06652581 Effectiveness Of Modified-Thoracoabdominal Nerve Block Perichondrial Approach (M-TAPA) In Laparoscopic Cholecystectomy
| NCT ID | NCT06652581 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Udayana University |
| Condition | Laparoscopic Cholecystectomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2024-09-12 |
| Primary Completion | 2024-11-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 42 participants in total. It began in 2024-09-12 with a primary completion date of 2024-11-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Goal of this clinical trial is to determine the advantages of using Peripheral Nerve Block by injecting drugs under the skin on both sides of the abdomen in the upper abdominal area in patients undergoing laparoscopic Cholecystectomy. Study participants will be divided into 2 groups, namely group P1 receiving Modified Thoracoabdominal Perichondrial Approach (M-TAPA) block anesthesia after laparoscopic cholecystectomy and group P2 only receiving intravenous opioids postoperatively. Peripheral nerve blocks on both sides of the upper abdomen are expected to be able to prolong the duration of pain relief, reduce the pain scale, and the total dose of pain medication needed postoperatively. The injection of this peripheral nerve block drug will be carried out by an anesthesiologist. Researchers will continue to anticipate the occurrence of side effects that can occur with strict monitoring and emergency care standards. This study will last up to 24 hours after surgery. The main question it aims to answer is: To prove that the amount of postoperative intravenous opioid consumption with M-TAPA block is lower than the control group.
Eligibility Criteria
Inclusion Criteria: 1. Patient 18-65 yeasr old 2. IMT 17.5-30 kg/m2 3. Patient with ASA I-II Exclusion Criteria: 1. Patient Refusal 2. Local Infection 3. Chronic Analgesia drug user
Contact & Investigator
WHO WHO
PRINCIPAL INVESTIGATOR
World Health Organization
Frequently Asked Questions
Who can join the NCT06652581 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Laparoscopic Cholecystectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06652581 currently recruiting?
Yes, NCT06652581 is actively recruiting participants. Contact the research team at ameliachristiana@student.unud.ac.id for enrollment information.
Where is the NCT06652581 trial being conducted?
This trial is being conducted at Denpasar, Indonesia.
Who is sponsoring the NCT06652581 clinical trial?
NCT06652581 is sponsored by Udayana University. The principal investigator is WHO WHO at World Health Organization. The trial plans to enroll 42 participants.